YENİ TANI HİPERTANSİF HASTALARDA DİPPER, NON-DİPPER HİPERTANSİYONUN ÜRİK ASİT DÜZEYİ VE KLİRENSİ İLE İLİŞKİSİ

Amaç:Günümüzde hipertansiyon (HT) gelişiminde ürik asit (ÜA) yüksekliğinin etkisi olduğunu bildirir çalışmalar mevcut iken dipper, non-dipper HT ile hiperürisemi ve ÜA klirensi arasındaki ilişki net değildir. Biz çalışmamızda; yeni tanı hipertansif hastalarda dipper, non-dipper HT’un, ÜA düzeyi ve klirensi ile ilişkisini değerlendirmeyi amaçladık. Materyal ve Metot:Çalışmamıza hastanemiz İç Hastalıkları ve Nefroloji kliniğinde takipli 59 yeni tanı primer HT hastası ve 24 sağlıklı birey dahil edildi. ÜA klirensi, 24-s idrarda sodyum, 24 saatlik ambulatuar KB ölçümü (24-s AKBM) ve ofis kan basıncı (KB) ölçümü yapıldı. Biyokimyasal parametreler için kan örneği alındı. Bulgular:Çalışmaya 59 HT hastası ile, 24 sağlıklı birey alındı. HT hasta grubunun korelasyon analizinde ÜA düzeyi ile kreatinin düzeyi arasında pozitif korelasyon(r=0.509) (p

The Relation Between Dipper, Non-dipper Hypertension and Uric Acid Level and Clearance in Newly Diagnosed Hypertensive Patients

Aim:While there are some studies reporting that higher levels of uric acid (UA) has an effect on the development of hypertension (HT), the relation between dipper, non-dipper HT and hyperuricemia and UA clearance is not clear. In our study;Weaimed to evaluate the relationship between dipper, non-dipper HT and UA level and clearance in newly diagnosed HTpatients. Materials and Methods:59 patients with diagnosed HT and 24 healthy individuals who were followed-up in departments of Internal Medicine and Nephrology, were included into the study. UA clearance and sodium in 24 hour urine were analyzed. Office blood pressure (BP) and 24-hour ambulatory blood pressure (24-h ABPM) were measured. Blood sample was obtained for biochemical analysis. Results:59 newly diagnosed HT patients and 24 healthy individuals were included into the study. The correlation analysis of the hypertensive patient group revealed a positive correlation between the UA and creatinine levels (r = 0.509) (p

PDF

___

1. K. Chaudhary, K. Malhotra, J. Sowers, A. AroorUric acid — key ingredient in the recipe for cardiorenal metabolic syndrome.Cardiorenal Medicine.2013;3(3):208-220 2. Maiuolo J, Oppedisano F, Gratteri S, Muscoli C, Mollace V. Regulation of uric asid metabolism and excreation. International Journal of Cardiology. 2016;213:8-14 3. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S,et al. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?Hypertension.2003;41(6):1183-90. 4. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. New England Journal of Medicine 2008;359(17):1811-21. 5. Nakagawa T, Kang DH, Feig D, Sanchez-Lozada LG, Srinivas TR, Sautin Y, et al. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. KidneyInternational.2006;69(10):1722-5.
6. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. Journal of Hypertension. 2008;26(2):269–275.
7. Sanchez-Lozada LG, Tapia E, Soto V, Avila-Casado C, Franco M, Wessale JL, et al. Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiology. 2008;108(4):69–78.
8. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension. 2005;45(1):18– 20.
9. Sundstro¨m J, Sullivan L, D’Agostino RB, Levy D, Kannel WB, Vasan RS. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence in the Framingham Heart Study. Hypertension. 2005;45(1):28-33.
10. Kalyon S, Uzun H, Helvacı A, Yenice N. Hipertansiyonun hiperürisemi ile ilişkisi. Okmeydanı Tıp Dergisi. 2011;27(3):138-43.
11. Messerli FH, Frohlich ED, Drenslinski GR, Suarez DH, Aristimuno GG. Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Annals of Internal Medicine. 1980;93(6):817-21.
12. Sanchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaria J, Nakagawa T, Rodríguez- Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces glomerular hypertension in normal rats. American Journal of Physiology. 2002;283(5):F1105-10.
13. Sanchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, Franco M, Rodríguez-Iturbe B, Johnson RJ. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. American Journal of Physiology.2008;295(4):F1134-41.
14. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Annals of Internal Medicine. 1999;131(1):7-13
15. Ouppatham S, Bancha S, Choovichian P. The relationship of hyperuricemia and blood pressure in the Thai army population. Journal of Postgraduate Medicine. 2008;54(4):259-62
16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, ; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press.2014;23(1):3-16.
17. Minutolo R, Agarwal R, Borrelli S, Chiodini P, Bellizzi V, Nappi F, Cianciaruso B, Zamboli P, Conte G, Gabbai FB, De Nicola L. Prognostic role of ambulatory blood pressure measurement in patients with nondialysis chronic kidney disease. Archives of Internal Medicine. 2011;171(12):1090–98.
18. Fagard RH, Thijs L, Staessen JA, Clement DL, De Buyzere ML, De Bacquer DA. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. Journal of Human Hypertension.2009;23(10):645–53.
19. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. Journal of the American Society of Nephrology. 2005;16(12):3553–62.
20. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, Hollenberg NK, Fisher ND. Uric acid and the state of the intrarenal renin– angiotensin system in humans. Kidney International. 2004;66(4):1465–70.
21. Afsar B, Elsurer R, Ozdemir FN, Sezer S. Uric acid and nocturnal nondipping in hypertensive patients with normal renal function Journal of Nephrology.2008 ;21(3):406-11
22. Tosu AR, Demir S, Selcuk M, Kaya Y, Akyol A, Ozdemir M, Tenekecioglu E. Comparison of inflammatory markers in non-dipper hypertension vs. dipper hypertension and in normotensive individuals: uric acid, C-reactive protein and red blood cell distribution width readings. Postepy w Kardiologii Interwencyjnej. 2014;10(2):98-103. 23. Tutal E, Sayın B, Ertugrul DT, Ibis A, Sezer S, Ozdemir N. Is there a link between hyperuricemia, morning blood pressure surge, and non-dipping blood pressure pattern in metabolic syndrome patients? International Journal of Nephrology and Renovascular Disease. 2013;6:71- 7.
24. Giallauria F, Predotti P, Casciello A, Grieco A, Russo A, Viggiano A, Citro R, Ravera A, at all. Serum uric acid is associated with non-dipping circadian pattern in young patients (30-40 years old) with newly diagnosed essential hypertension. Clinical and Experimental Hypertension. 2016;38(2):233-7.
25. Mrug S, Mrug M, Morris AM, Reynolds N, Patel A, Hill DC, Feig DI. Uric Acid Excretion Predicts Increased Blood Pressure Among American Adolescents of African Descent. The American Journal of the Medical Sciences. 2017Apr;353(4):336-41. 26. Li F, Guo H, Zou J, Chen W, Lu Y, ZhangX,Fu C, Xiao J, Ye Z. The Association of Urinary Sodium and Potassium with Renal Uric Acid Excretion in Patients with Chronic Kidney Disease. Kidney Blood Pressure Research. 2018;43(4):1310-21.